Introduction {#s1}
============

The effect of sodium reduction (SR) on blood pressure (BP) is smaller in persons with normal blood pressure than in hypertensive persons (Graudal et al., [@B4], [@B5]). A recent dose-response analysis showed a dose-response relationship between SR and effect on BP in study populations with a mean BP above 130/80 mmHg, but not in study populations with a mean BP below 130/80 mmHg, unless SR was applied on study populations with an extreme sodium intake above about 6 g sodium (14.5 g salt) (Graudal et al., [@B6]). These findings indicate that the effect of SR depends on the baseline blood pressure, the baseline sodium intake and the quantity of SR. Hypothetically, the duration of SR could also be an important determinant of the effect of SR on BP, but a detailed analysis of 15 longitudinal RCTs, which investigated participants repeatedly during up to 6 weeks, showed that the effect of SR on BP was similar during the observation period from 1 to 6 weeks indicating that the duration of SR beyond 1 week does not influence the effect of SR on BP (Graudal et al., [@B6]).

Our previous meta-analysis showed that the effect of SR on SBP was higher in Asian hypertensive persons (10.2 mmHg) than in White (5.5 mmHg) and Black hypertensive persons (6.4 mmHg) (Graudal et al., [@B4]). Furthermore the effect of SR on SBP was higher in Black persons with a normal blood pressure (4.0 mmHg) than in Asian (1.3 mmHg) and White persons with a normal BP (1.3 mmHg) (Graudal et al., [@B4]). However, a subsequent analysis of Blacks showed that the difference between Blacks and Whites was small, if studies investigating extreme sodium reductions were eliminated (Graudal and Alderman, [@B3]). The reason for ethnic differences are not defined and could be due to different baseline blood pressures, sodium intakes and doses of SR or other confounders, rather than genetic differences.

The purpose of the present supplementary analysis of our previous meta-analysis of randomized trials (Graudal et al., [@B5]) was to analyze the significance of ethnicity on the effect of SR on BP by estimating the effect of SR on BP in Asians, Blacks and Whites under conditions, which were adjusted with respect to baseline BP, baseline sodium intake and quantity of SR.

Material
========

Relevant studies were retrieved from a pool of 167 RCTs published in the period 1973--2010 and identified in a Cochrane review in 2011 (Graudal et al., [@B5]). Search methods for identification of these 167 studies are previously described in detail (Graudal et al., [@B5]).

Methods {#s2}
=======

Eligibility criteria
--------------------

Trials randomizing participants to two different sodium intakes were included provided that the sodium intake was measured as 24-h urinary excretion (Graudal et al., [@B5]). Baseline BP was used to define the study groups to ensure that the baseline BP was similar across the three ethnic study groups. The most extreme sodium intake in the world\'s populations is about 6 g sodium (14.5 g salt) (McCarron et al., [@B9]; Powles et al., [@B11]), corresponding to about 250 mmol, and we therefore excluded studies with sodium intakes above this level, as such intakes reflected an experimental situation rather than a population norm. In a series of longitudinal RCTs we have showed that the effect of SR on BP is at maximum after 1 week (Graudal et al., [@B6]). As we do not know whether this effect is reached before 1 week, we excluded studies with a shorter duration than 1 week.

In order to avoid excluding the relatively few studies, which have been performed in Blacks and Asians, the baseline systolic BP (SBP) range of these study groups were used to define the baseline SBP range of the white comparator study groups.

Bias
----

The following factors were analyzed across the defined ethnic groups to evaluate the comparability of the groups: Age, baseline SBP, baseline diastolic BP (DBP), baseline sodium intake and the quantity of sodium reduction.

Statistical analysis
--------------------

In this re-analysis featuring improved control for blood pressure and the extent of salt intake and salt reduction the individual study data were integrated in meta-analyses separately for Asians, Blacks, and Whites, and the integrated summary data for each of the groups were then compared versus each other. As well the separate meta-analyses as the comparisons of the summary data for each ethnic group were performed by means of the inverse variance method (continuous data) in Review Manager (RevMan) \[Computer program\], version 5.1. Copenhagen: The Nordic Cochrane Centre, the Cochrane Collaboration, 2008.

A supplementary meta-regression analysis of Ethnicity versus effect on blood pressure (separate analyses for SBP and DBP) adjusted for amount of sodium reduction, baseline blood pressure (SBP and DBP), age, and the duration of the sodium reduction intervention was performed by means of the multiple regression analysis package in Statview 5.0.

Results {#s3}
=======

Study selection
---------------

The study groups were defined from 167 references (Graudal et al., [@B5]). Some references reported separate data on sodium sensitive and sodium resistant participants. These were integrated before inclusion in the meta-analysis. Some references included separate analyses on hypertensive and normotensive persons or on different ethnic groups. These were included as separate data. The total number of study groups in the 167 references (Graudal et al., [@B5]) was 184. 16 study groups of mixed ethnic populations were excluded. Two Black populations with duration of sodium reduction less than 7 days were excluded. As it was the objective to match studies for each ethnic group according to range of SBP, all Asian and Black populations were ranked with respect to baseline SBP. Ten Asian study populations had a mean baseline SBP in the range 113--158 mm Hg and 12 Black populations had mean baseline SBP in the range of 108--156 mmHg. We excluded the one study with the lowest baseline SBP of 108 mmHg, as this was outside the 113--158 range defined by the Asian populations. In this study SBP raised 0.5 mmHg when sodium intake was reduced. The remaining 11 studies had a baseline SBP range of 113--156 mmHg and thus were comparable to the Asian population concerning this range. As SBP in the 144 studies of white populations varied in the range of 105--179 mmHg, 15 with baseline SBP above 158 mmhg and 18 with a baseline SBP in the range of 105--112 mmHg were excluded. Five white study populations with no information on baseline SBP were also excluded, leaving 106 study populations with a baseline SBP in the range of 113--158. Then 1 study of Asians, 2 studies of blacks and 21 studies of whites with a high sodium intake above 250 mmol and 11 white populations with duration of SR less than 7 days were excluded. Thus, 9 Asian populations (6 references, Table [1](#T1){ref-type="table"}), 9 black populations (7 references, Table [1](#T1){ref-type="table"}) and 74 white populations (70 references, Table [1](#T1){ref-type="table"}) standardized with respect to the range of baseline blood pressure, duration of SR (at least 7 days) and baseline sodium intake (at maximum 250 mmol) were included.

###### 

**Baseline data, blood pressure outcome data and references of included studies**.

  **Eth**.   **Authors**      **Dur**.   **BP**   **N**   **Age**   **HS**   **LS**   **B SBP**   **B DBP**   **E SBP**   **SSE**   **E DBP**   **DSE**   **References**
  ---------- ---------------- ---------- -------- ------- --------- -------- -------- ----------- ----------- ----------- --------- ----------- --------- ---------------------------------------------------
  A          Ishimitsu        7          N        7       53        217      22       116         77          −2.0        4.3       −2.0        3.6       Clin. Sci. 1996; 91, 293--298.
  A          Ishimitsu        7          H        23      55        217      24       157         95          −15.7       6.0       −5.5        3.2       Clin. Sci. 1996; 91, 293--298.
  A          Uzu              7          H        70      51        204      31       154         94          −15.6       7.4       −5.0        3.1       AJH 1999; 12, 35--39.
  A          Suzuki           7          H        20      59        167      51       157         92          −4.0        2.0       −2.6        1.3       Hypertension 2000; 35, 864--868.
  A          Nakamura         42         N        38      47        240      216      113         66          2.0         2.0       −5.5        3.0       Circ. J. 2003;67, 530--534.
  A          Nakamura         42         TH       26      47        240      216      140         90          −5.8        4.9       −1.3        3.3       Circ. J. 2003;67, 530--534.
  A          Takahashi        365        N        341     56        248      209      123         74          −2.3        1.2       −1.2        1.0       J. Hypertens. 2006; 24, 451--8.
  A          Takahashi        365        TH       107     56        248      209      143         83          −5.2        2.4       0.1         1.7       J. Hypertens. 2006; 24, 451--458.
  A          He               42         H        29      47        176      108      142         92          −5.4        1.9       −2.2        1.0       Hypertension 2009; 54, 482--488.
  B          Dubbert          90         TH       67      61        194      160      138         86          −1.4        3.8       −0.5        1.7       Behav. Ther. 1995; 26, 721--732.
  B          Sacks            30         N        68      48        141      64       129         84          −6.4        1.2       −4.0        0.8       NEJM 2001; 344, 3--10.
  B          Sacks            30         H        46      48        141      64       143         89          −8.6        1.2       −5.3        0.8       NEJM 2001;344:3-10.
  B          Appel            105        TH       142     66        145      116      128         71          −5.0        1.7       −2.9        1.2       Arch. IM 2001; 161, 685--693.
  B          Palacios         21         N        15      12        109      35       113         59          3.4         1.5       −0.1        1.9       JCEM 2004; 89, 1858--1863.
  B          Forrester (Ni)   21         N        58      47        127      53       115         73          −4.8        1.5       −3.2        1.0       J. Hum. Hypertens. 2005; 19, 55--60.
  B          Forrester (Ja)   21         N        56      41        155      68       126         76          −5.1        1.5       −2.2        1.5       J. Hum. Hypertens. 2005; 19, 55--60.
  B          Swift            28         H        40      50        167      89       156         100         −8.0        2.1       −3.0        1.1       Hypertension 2005; 46, 308--312.
  B          He               42         H        69      50        165      121      149         90          −4.8        1.2       −2.2        0.7       Hypertension 2009; 54, 482--488.
  W          Skrabal          14         N        20      23        200      50       125         73          −2.7        2.1       −3.0        1.5       Lancet 1981; II, 895--900.
  W          Ambrosioni       42         H        25      23        120      60       130         75          −2.2        1.6       −0.4        1.2       Hypertension 1982; 4, 789--794.
  W          Beard            84         TH       90      49        161      37       141         87          −5.2        4.9       −3.4        2.9       Lancet. 1982; II, 455--458.
  W          Puska            72         N        38      40        167      77       131         82          −1.5        4.5       −2.1        2.8       Lancet 1983; I, 1--5.
  W          Puska H          72         H        34      40        167      77       147         98          1.8         5.6       0.5         3.1       Lancet 1983; I, 1--5.
  W          Watt             28         H        18      52        143      87       150         91          −0.5        1.5       −0.3        0.8       BMJ 1983; 286, 432--6.
  W          Skrabal          14         N        52      23        194      38       121         64          −3.1        4.4       −1.9        2.6       Hypertension 1984; 6, 152--158.
  W          Fagerberg        63         H        30      51        195      96       149         98          −3.7        7.1       −3.1        4.1       BMJ 1984; 288, 11--14.
  W          Maxwell          84         H        30      47        200      39       148         98          −2.0        6.7       2.0         3.8       Arch. IM 1984; 144, 1581--1584.
  W          Richards         28         H        12      36        180      80       137         86          −4.0        2.8       −3.0        2.3       Lancet 1984; I, 757--761.
  W          Tuthill          56         N        191     16        126      65       113         70          0.0         1.1       0.0         1.3       Tox. Ind. Health 1985; 1, 35--43.
  W          Skrabal          14         N        62      23        194      40       120         64          −3.1        2.2       −1.5        0.9       SJCLI 1985; 176(S), 47--57.
  W          Teow             14         N        9       25        240      40       114         66          −0.6        1.2       −2.7        1.4       Clin. Exp. Hypertens. 1986; A7, 1681--1695.
  W          ANHMRC           84         H        100     53        150      80       150         94          −4.8        3.9       −4.2        1.9       J. Hypertens. Suppl. 1986; 4, S629-S637.
  W          Fuchs            9          N        17      20        241      12       117         57          −3.6        2.2       1.9         1.0       Braz. J. Med. Biol. Res. 1987; 20, 25--34.
  W          Morgan           60         TH       20      61        135      78       143         82          −6.0        9.0       −4.0        4.3       Lancet 1987; I, 227--230.
  W          Grobee           42         H        40      24        129      57       143         78          −0.8        1.5       −0.8        1.4       BMJ 1987; 293, 27--29.
  W          McGregor         30         TH       15      52        183      83       150         97          −13.0       3.3       −9.0        3.1       BMJ 1987; 294, 531--534.
  W          Morgan           14         H        8       63        135      68       149         96          −7.0        3.0       −6.0        3.0       J. Hypertens. 1988; 6(Suppl. 4), S652--S654.
  W          Sudhir           12         N        6       35        163      29       129         81          −7.9        3.4       −5.0        2.1       Clin. Sci. 1989; 77, 605--610.
  W          Hargreaves       14         N        8       23        155      49       129         66          −6.0        2.2       −3.0        2.0       Clin. Sci. 1989; 76, 553--557.
  W          ANHMRC           48         H        103     58        153      90       154         95          −5.5        1.5       −2.8        0.8       Lancet 1989; 1, 399--402.
  W          Schmid           7          N        9       32        210      20       125         75          −3.0        1.9       3.0         1.6       J. Hypertens. 1990; 8, 277--283.
  W          Schmid H         7          H        9       36        210      29       147         93          −6.0        3.1       −1.9        2.1       J. Hypertens. 1990; 8, 277--283.
  W          Sharma           7          N        40      25        239      25       113         71          −2.1        1.1       −3.1        1.0       Hypertension 1990; 16, 407--413.
  W          Friberg          13         N        10      33        152      35       114         69          0.0         2.0       −1.0        2.0       Hypertension 1990; 16, 121--130.
  W          Del Rio          14         H        15      49        190      90       149         94          −3.4        2.0       −1.1        1.8       Rev. Clin. Esp. 1990; 186, 5--10.
  W          Parker           28         TH       59      52        142      69       138         85          1.3         2.2       0.6         0.9       Hypertension 1990; 16, 398--406.
  W          Howe             28         N        90      13        179      98       115         60          −1.0        0.7       −0.6        0.7       J. Hypertens. 1991; 9, 181--186.
  W          Mascioli         28         N        48      52        179      109      131         84          −3.6        0.9       −2.3        0.8       Hypertension 1991; 17(Suppl. 1), I21--I26.
  W          Egan H           7          H        18      35        214      20       124         78          −2.7        5.5       −1.7        3.5       AJH 1991; 4, 416--421.
  W          Gow              7          N        9       0         111      17       120         68          −8.0        1.6       −3.0        2.2       EJCP 1992; 43, 635--638.
  W          Cobiac           28         N        106     67        148      75       132         77          −2.8        1.6       −1.0        1.8       J. Hypertens 1992; 10, 87--92.
  W          Benetos          28         H        20      42        163      85       149         93          −6.5        1.9       −3.7        1.3       J. Hypertens, 1992; 10, 355--360.
  W          Sciarrone        56         TH       91      54        134      52       136         83          −5.8        4.1       −0.4        2.3       J. Hypertens 1992; 10, 287--298.
  W          Nestel           42         N        66      66        157      91       125         73          −3.2        2.7       −1.4        2.0       J. Hypertens 1993; 11, 1387--1394.
  W          Del Rio          14         H        30      49        199      48       156         96          −1.4        1.8       −0.5        1.3       JIM 1993; 233, 409--414.
  W          Zoccali          7          H        15      45        217      54       144         92          −14.0       2.5       −8.0        1.4       J. Hypertens. 1994; 12, 1249--1253.
  W          Jula             365        H        76      44        166      109      147         97          −6.7        3.9       −3.8        1.7       Circulation 1994; 89, 1023--1031.
  W          Howe             42         TH       56      55        158      78       145         81          −4.2        2.9       −1.5        1.9       J. Hum. Hyp. 1994; 8, 43--49.
  W          Miller           14         N        36      23        191      133      118         62          1.9         1.6       −0.1        1.5       Psychosom. Med. 1995; 57, 381--389.
  W          Fliser           7          N        7       26        203      23       114         71          −1.1        2.9       −0.7        1.8       EJCI 1995; 25, 39--43.
  W          Arrol            182        TH       181     55        122      106      145         89          −0.4        3.4       −1.2        2.1       NZ Med. J. 1995; 108, 266--268.
  W          Dubbert          90         TH       55      63        200      145      148         85          −1.4        3.8       −0.5        1.7       Behav. Ther. 1995; 26, 721--732.
  W          Grey             7          N        34      23        185      52       116         70          1.0         1.2       1.0         0.9       AJH 1996; 9, 317--322.
  W          Feldman H        7          H        8       27        182      6        126         79          2.6         2.9       1.6         1.8       CPT 1996; 60, 444--451.
  W          Schorr           28         N        16      64        166      105      140         84          −1.0        2.7       0.0         1.7       J. Hypertens 1996; 14, 131--135.
  W          Cappucio         30         N        18      67        167      91       149         85          −8.1        2.8       −3.9        1.5       Lancet 1997; 350, 850--854.
  W          van Buul         196        N        232     28        140      75       122         71          0.0         1.8       0.0         1.2       Hyp. Preg. 1997; 16, 335--346.
  W          Meland           56         H        16      50        191      125      146         95          −4.0        2.5       −3.0        1.4       SJCLI 1997; 57, 501--506.
  W          Feldman          7          N        8       33        207      48       130         82          0.0         5.5       0.0         3.6       AJH 1999; 12, 643--647.
  W          Barba            7          N        7       32        177      23       118         74          −3.2        5.5       −2.1        3.5       J. Hypertens. 2000; 18, 615--621.
  W          Sacks            30         N        54      49        141      64       129         84          −4.0        1.2       −1.4        0.8       NEJM 2001; 344, 3--10. AIM 2001; 135, 1019--1028.
  W          Sacks H          30         H        37      49        141      64       143         89          −6.6        1.2       −2.7        0.8       NEJM 2001; 344, 3-10. AIM 2001; 135, 1019--1028.
  W          Seals            90         H        35      64        132      86       143         78          −8.0        2.6       −2.0        1.7       J. Am. Coll. Cardiol. 2001; 38, 506--513.
  W          Appel TH         105        TH       471     66        145      105      128         71          −4.0        1.0       −1.6        0.7       Arch. IM 2001; 161, 685--693.
  W          Johnson          14         H        40      69        185      112      150         83          −4.5        2.1       −0.6        1.5       J. Hypertens. 2001; 19, 1053--1060.
  W          Manunta          14         H        20      48        177      67       152         99          −5.2        2.0       −3.3        2.0       Hypertension 2001; 38, 198--203.
  W          Kleij            7          N        27      24        236      50       119         74          0.2         3.3       0.1         2.1       JASN 2002; 13, 1025--1033.
  W          Kerstens         7          N        28      23        248      42       115         72          3.1         2.0       2.0         1.3       JCEM 2003; 88, 4180--4185.
  W          Nowson           28         N        92      45        139      51       123         75          −0.7        0.8       0.0         0.6       J. Nutr. 2003; 133, 4118--4123.
  W          Palacios         21         N        8       13        120      34       113         55          −0.1        1.5       4.2         1.7       JCEM 2004; 89, 1858--1863.
  W          Gates            28         H        12      64        155      60       140         84          −3.0        1.8       −1.2        1.5       Hypertension 2004; 44, 35--41
  W          Damgaard         7          N        12      57        188      59       124         77          0.0         4.7       0.0         3.0       AJP RICP 2006; 290, R1294--R1301.
  W          Melander         28         M        39      53        140      51       144         91          −6.0        1.2       −2.3        0.9       J. Hypertens. 2007; 25, 619--627.
  W          Dengel           8          H        28      63        191      36       152         79          −10.0       3.6       −4.0        3.6       Physiol. Res. 2007; 56, 393--401.
  W          Jessani          7          N        184     50        138      57       122         79          −1.0        0.8       −1.0        0.8       AJH 2008; 21: 1238--1244.
  W          Dickinson        14         N        29      53        156      64       116         73          −5.0        1.5       −1.0        1.1       AJCN 2009; 89, 485--490.
  W          He               42         H        71      52        165      110      146         90          −4.8        1.2       −2.2        0.7       Hypertension 2009; 54, 482--488.
  W          Meland           56         H        46      56        126      83       156         93          −5.0        3.8       −5.0        1.4       SJPHC 2009; 27, 97--103.
  W          Nowson TH        98         TH       35      59        113      69       130         80          −5.5        2.7       −3.6        1.6       Nutr. Res. 2009; 29, 8--18.
  W          Nowson           98         N        59      59        113      69       131         81          −1.1        2.0       0.3         1.5       Nutr. Res. 2009; 29, 8--18.
  W          Weir             28         H        132     52        208      85       139         87          −9.4        1.0       −5.7        0.7       J. Cardiovasc. PT 2010; 15, 356--363.
  W          Starmans-Kool    14         N        10      32        191      94       114         65          −2.0        3.4       0.0         3.4       J. Appl. Physiol. 2011; 110, 468--471.

*Eth, Ethnicity; A, Asian; B, Black; W, White; NI, Nigeria; Ja, Jamaica; ANHMRC, Australian National Health and Medical Research Council; Dur, Duration (Days); BP, Blood pressure; H, Hypertension; TH, Treated hypertension; N, Normotension; Age, Age (years); HS, High sodium intake (mmol); LS, Low sodium intake (mmol); B., Baseline; E, Effect; SBP, Systolic blood pressure; DBP, Diastolic blood pressure; SSE, Systolic blood pressure standard error; DSE, Diastolic blood pressure standard error*.

Table [1](#T1){ref-type="table"} shows the references, baseline characteristics and the individual study data of the 9 Asian, 9 Black, and 74 White populations included in the present study. Summary measures of baseline variables and BP effects of Asians, Blacks and Whites are shown in Table [2](#T2){ref-type="table"}. There was no statistical difference in sex distribution although there was a trend toward a higher fraction of females in Asians. Asians were significantly older and had a significantly higher sodium intake than Blacks and Whites. Still the effect of SR on SBP and DBP did not differ from the effect in Blacks and Whites.

###### 

**Baseline variables and blood pressure effects in populations of Whites, Blacks, and Asians balanced with respect to baseline blood pressure unadjusted and adjusted for sodium reduction**.

                               **Asians (A)**              **Blacks (B)**              **Whites (W)**              **W (A)[^\*^](#TN1){ref-type="table-fn"}**   **Significance**
  ---------------------------- --------------------------- --------------------------- --------------------------- -------------------------------------------- --------------------------------------------------------------------
  N studies                    9                           9                           74                          39                                           
  N participants               661                         561                         3782                        2779                                         
  Female %                     58                          45                          45                                                                       0.21
                               Mean (95% CI)                                                                                                                    
  Sodium reduction (SR) mmol   97.89 \[46.46, 149.31\]     63.16 \[48.86, 77.46\]      102.91 \[92.20, 113.63\]    66.12 \[58.49, 73.75\]                       B vs. W 0.006
  Age, years                   52.30 \[49.52, 55.08\]      46.83 \[25.41, 68.25\]      43.04 \[39.64, 46.44\]      49.14 \[43.57, 54.70\]                       A vs. W: 0.03
  Baseline SBP, mm Hg          138.29 \[126.71, 149.87\]   132.84 \[125.30, 140.37\]   133.58 \[130.75, 136.41\]   137.24 \[133.39, 141.09\]                    NS
  Baseline DBP, mm Hg          84.68 \[78.03, 91.33\]      80.90 \[75.01, 86.80\]      80.69 \[78.20, 83.18\]      82.43 \[79.04, 85.82\]                       NS
  Baseline sodium intake       217.48 \[194.68, 240.28\]   148.70 \[133.28, 164.12\]   167.67 \[161.17, 174.17\]   137.43 \[133.17, 141.68\]                    A vs. B and A vs. W: 0.00001
  Effect SBP, mm Hg            −3.83 \[−6.35, −1.31\]      −4.68 \[−7.10, −2.26\]      −3.24 \[−4.01, −2.46\]      −3.06 \[−3.94, −2.18\]                       NS (Figure [1](#F1){ref-type="fig"})
  Effect DBP, mm Hg            −1.99 \[−3.04, −0.94\]      −2.99 \[−3.95, −2.02\]      −1.54 \[−2.05, −1.03\]      −1.51 \[−2.04, −0.98\]                       B vs. W: 0.04 B vs. W (A): 0.013 (Figure [1](#F1){ref-type="fig"})

*Sodium reduction adjusted to Blacks by elimination of all studies of Whites with SR \> 90 mmol*.

Figure [1](#F1){ref-type="fig"} shows the comparisons between ethnic groups of the summary measures of SBP and DBP. Cross-sectional data for all included studies are shown in Figure [1](#F1){ref-type="fig"}, lines 1,3,5,8, 10, and 12. In addition the results from studies investigating at least two ethnic groups are shown in lines 2, 4, 6, 9, 11, and 13. The differences between the ethnic groups are substantially smaller than in the original analyses (Graudal et al., [@B5]). The effect of SR on DBP showed a significant difference between Blacks and Whites. The differences were generally smaller and not statistically significant when comparing the data obtained from studies investigating two or three ethnic groups in identical studies (Figure [1](#F1){ref-type="fig"}, lines 2, 4, 6, 9, 11, and 13) than when comparing data across studies (Figure [1](#F1){ref-type="fig"}, lines 1,3,5,8, 10, and 12).

![**Differences in effect of sodium reduction on systolic and diastolic blood pressure (SBP and DBP) between Asians (A), Blacks (B), and Whites (W)**. E, Ethnic group; IS, Identical study.](fphys-06-00157-g0001){#F1}

Supplementary analyzes
----------------------

As the attempt to adjust the ethnic groups did not completely succeed, we supplied with a supplementary meta-regression analysis of ethnicity versus effect on blood pressure adjusted for amount of sodium reduction, baseline blood pressure, age, the duration of the sodium reduction intervention and the female percentage. This analysis shows that there is a statistically significant difference in SBP effect between the ethnic groups, both unadjusted and adjusted, but clinically the difference is small (about 1 mmHg) (Table [3](#T3){ref-type="table"}). There were no differences in DBP effect between the ethnic groups (Table [3](#T3){ref-type="table"}).

###### 

**Regressionkoefficient, mmHg** (***p***-**value) in univariate and multivariate regressionanalyses adjusted for additional confounders**.

                **1: Ethnicity *N* = 92 (univariate)**   **2: 1 + Sodium reduction**   **3: 2 + Baseline blood pressure**   **4: 3 + Age**   **5: 4 + Duration**   **6: 5 + Female%**
  ------------- ---------------------------------------- ----------------------------- ------------------------------------ ---------------- --------------------- --------------------
  Effect SBP,   1.28 (0.039)                             1.32 (0.032)                  1.15 (0.026)                         1.08 (0.032)     1.12 (0.03)           1.07 (0.043)
  Effect DBP,   0.63 (0.083)                             0.60 (0.10)                   0.50 (0.14)                          0.46 (0.17)      0.55 (0.11)           0.61 (0.077)

In another additional analysis we excluded 35 study populations of Whites with a high sodium reduction to adjust the quantity of sodium reduction in Blacks and Whites (Table [2](#T2){ref-type="table"}, column 5). This only changed the outcome blood pressures marginally (Figure [1](#F1){ref-type="fig"}, lines 7 and 14).

Discussion {#s4}
==========

The present study, which attempted to adjust for baseline blood pressure and the quantity of sodium reduction showed that Asians had a non-significant trend toward a higher BP response to SR than whites, but they were also older, had a non-significantly higher mean baseline BP and a significantly higher baseline sodium intake (Table [2](#T2){ref-type="table"}). Blacks had a non-significant trend toward a higher SBP response and a significant trend toward a higher DBP response to SR than Whites while matching the Whites on other baseline variables except quantity of SR (Table [2](#T2){ref-type="table"}). The difference was unchanged after adjusting for quantity of SR (Table [2](#T2){ref-type="table"}). The supplementary meta-regression analyses adjusted for confounders confirmed that the ethnic differences in blood pressure response to sodium reduction were small, although marginally significant for SBP. Thus there may be an unexplained additional effect of SR on BP, especially in Blacks, which however is small compared to previous unadjusted findings (Graudal et al., [@B5]). One explanation could be that there are few studies in Asians and Blacks. This might increase the risk of publication bias as suggested by our previous cumulative meta-analysis (Graudal et al., [@B4]), which showed a higher effect of SR on BP after publication of the first 7--8 studies, whereas a smaller and more stable effect was manifest after the publication of about 15 studies. This assumption is also indicated by the fact that the comparisons of Asian, Black, and White study populations from identical studies showed no statistical differences between the ethnic groups (Figure [1](#F1){ref-type="fig"}). The heterogeneity between the baseline characteristics was large and therefore it was difficult to adjust all 3 study-groups to identical baseline values, because adjustment of one baseline value created another imbalance between other baseline variables. However, in spite of these variations, the differences in effects of SR on BP between the ethnic groups were small.

Our results are in accordance with a recent co-operation between Cuban, Canadian, and American researchers, who compared Black and White Cubans living under similar socio-economic conditions and found that "skin color was unrelated to mean blood pressure or hypertensive status" (Ordúñez1 et al., [@B10]). The background for this study was the assumption by many scientists that the excess burden of hypertension among blacks was an inevitable phenomenon. However, the authors concluded that social conditions rather than ethnic group may determine the general development of excess hypertension in Blacks (Ordúñez1 et al., [@B10]). In that context it should be emphasized that the sodium reduction RCTs of Whites generally are performed in Europeans and Americans, whereas the RCTs of Blacks are performed in Black Americans and Africans, who socioeconomically are not comparable to White Americans and Europeans. In that context it is interesting that after adjustment for important confounders the difference between Whites and Blacks was small. If we had been able to adjust for socio-economic differences this last small difference in effect on DBP might have disappeared.

The possibility that socioeconomic conditions has an important influence on BP may also be reflected in the BP development in the United States during the 20th century. Not only did BP fall markedly in each new 10--year birth cohort from 1887 to 1975, the slope of the BP increase with age of each of these cohorts also decreased (Goff et al., [@B2]). The total fall in BP during the 20th century was dramatic and cannot solely be explained by the introduction of antihypertensive treatments, low-fat diets or decrease in the use of tobacco, as the BP fall started long before these interventions. The enormous socio-economic development in the United States is a much more likely explanation. Recently the fall in BP seems to have stopped, maybe due to the present overweight epidemic (Goff et al., [@B1]). In the Cuban study the mean SBP was about 120 mmHg (adults \> 15 years) and the percentage of hypertension was about 31% in both Blacks and Whites. In US the mean SBP was about 127 mmHg for Blacks and about 122 mmHg for Whites (adults \> 18 years) (Wright et al., [@B13]). The percentage of hypertension is about 37% for Blacks and 30% for Whites (Wright et al., [@B13]).

An IOM report from 2004 recommended that all African Americans eat less than 1500 mg of sodium, whereas whites could eat up to 2300 mg of sodium (Institute of Medicine, [@B7]). In contrast the recent IOM report from 2013 (Institute of Medicine, [@B8]) concluded "Given this background, overall, the committee found that the available evidence on associations between sodium intake and direct health outcomes is consistent with population-based efforts to lower excessive dietary sodium intakes, but it is not consistent with recommendations that encourage lowering of dietary sodium in the general population to 1500 mg per day. Further, as noted in the 2010 DGAC report, population subgroups, including those with diabetes, CKD, or preexisting CVD, individuals with hypertension, pre-hypertension, persons 51 years of age and older, and African Americans represent, in aggregate, a majority of the general U.S. population. Thus, when considered in light of the current state of the evidence on associations between sodium intake and direct health outcomes for these subgroups, except when data specifically indicate they are different, there is not sufficient evidence to support treating them differently from the general U.S. population." The present study is in accordance with the 2013 IOM conclusion indicating no true ethnic dependent sensitivity to sodium.

In conclusion, ethnic differences in blood pressure response to sodium reduction seem smaller than previously observed. When the effect of SR on BP was adjusted for baseline blood pressure and quantity of sodium reduction there was a small statistically significant ethnic difference in SBP response and DBP response depending on the statistical method used, but the comparisons of Asian, Black and White study populations from studies investigating ethnic groups in identical studies showed no statistical differences in effect of SR on SBP or DBP between the ethnic groups in accordance with the conclusion of the 2013 IOM report. Whether the small observed differences in the present study are due to socio-economic factors or genetic factors remains to be setteled. Public guidelines like the American Guidelines (U.S. Department of Agriculture and U.S. Department of Health and Human Services [@B12]) might be changed to recommend the same levels of sodium intake irrespective of ethnicity.
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